Human Anti-CD22 Recombinant Antibody (clone MJ-7) (CAT#: HPAB-0206-LSX)

Recombinant monoclonal antibody to CD22. Clone MJ-7 is a human monoclonal antibody that can be potentially used in the treatment of B-cell malignancy.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
WB

Figure 1 Western blot analysis of purified MJ-7.

Figure 1 Western blot analysis of purified MJ-7.

Size of molecular weight markers are indicated (kDa).

Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.

Figure 2 Immunoreactivity of monomeric MJ-7 (closed triangle) and MLZ-wt (closed square) after incubation in human serum at 37°C over a period of 6 days.

Figure 2 Immunoreactivity of monomeric MJ-7 (closed triangle) and MLZ-wt (closed square) after incubation in human serum at 37°C over a period of 6 days.

Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.

Figure 3 Biophysical stability of IMAC-purified scFv variants.

Figure 3 Biophysical stability of IMAC-purified scFv variants.

Immunoreactivity with CD22+ Raji cells was assayed by flow cytometry after incubating the constructs at 37°C in human serum for various time periods. The half-life was determined as the time point with 50% of the initial binding activity.

Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.

Figure 4 Affinity and specificity of wild-type scFv and stability engineered scFv.

Figure 4 Affinity and specificity of wild-type scFv and stability engineered scFv.

(a) Equilibrium-binding curves for MAb LL2 (open circle); MLZ-wt (closed square) and MJ-7 (closed triangle) as determined by flow cytometry. Binding activity to Raji cells at indicated concentrations is shown as median fluorescence intensity (MFI) minus background fluorescence. Measurements were performed in triplicate; standard deviations are shown as bars. Binding affinity constants (Kd) were determined by fitting the cell binding data to the nonlinear regression model according to the Levenberg-Marquard method. (b) Epitope specificity was determined by competition experiments and analyzed by flow cytometry. MLZ-wt (closed square) and MJ-7 (closed triangle) competed with the MAb LL2 for binding to the CD22 antigen on Raji cells. Results are shown as percent binding inhibition of MAb LL2 at a concentration of 100 nM when incubating tumor cells with various concentrations of scFvs.

Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.

Figure 5 Internalization of antibodies into living tumor cells.

Figure 5 Internalization of antibodies into living tumor cells.

Alexa-488-labeled MAb LL2 (a,b) or scFv MJ-7 (c,d), each at a concentration of 50 μg/ml, were incubated with Raji cells (5 × 10⁵) for 30 min either at 4°C (a,c) or 37°C (b,d) before analysis by confocal microscopy.

Arndt, M. A., Krauss, J., Schwarzenbacher, R., Vu, B. K., Greene, S., & Rybak, S. M. (2003). Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma. International journal of cancer, 107(5), 822-829.


Specifications

  • Host Species
  • Human
  • Derivation
  • Humanized
  • Type
  • Human IgG
  • Specificity
  • Human CD22
  • Species Reactivity
  • Human
  • Clone
  • MJ-7
  • Applications
  • ELISA, FC, WB
  • Related Disease
  • B-cell malignancy

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • This antibody has been tested for use in Western Blot.

Target

  • Alternative Names
  • CD22 Molecule; CD22 Antigen; Sialic Acid Binding Ig-Like Lectin 2; Sialic Acid-Binding Ig-Like Lectin 2; B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2; SIGLEC2; BL-CAM

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone MJ-7"

See other products for "CD22"

Immunotoxin

CAT Product Name Application Type
AGTO-G077E Anti-CD22 immunotoxin RFB4 (IgG)-PE Cytotoxicity assay, Function study
AGTO-G077D Anti-CD22 immunotoxin RFB4 (IgG)-DT Cytotoxicity assay, Function study
AGTO-G077G Anti-CD22 immunotoxin RFB4 (IgG)-Gel Cytotoxicity assay, Function study
AGTO-G077R Anti-CD22 immunotoxin RFB4 (IgG)-RTA Cytotoxicity assay, Function study
AGTO-G077S Anti-CD22 immunotoxin RFB4 (IgG)-Sap Cytotoxicity assay, Function study

Humanized Antibody

Fab Glycosylation

CAT Product Name Application Type
Gly-001LC Recombinant Anti-Human CD22 Antibody (Fab glycosylation) ELISA, FC Mouse antibody

Fc Glycosylation

CAT Product Name Application Type
Gly-111LC Recombinant Anti-Human CD22 Antibody (Fc glycosylation) ELISA Chimeric antibody (mouse/human)

Blocking Antibody

CAT Product Name Application Type
NEUT-315CQ Rat Anti-CD22 Recombinant Antibody (clone 2D6) Block Rat IgG1, κ

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0545 Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB) IP, WB Rabbit IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-176 Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-198 Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for HPAB-0206-LSX. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare